A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis

BACKGROUND: The combination of rifapentine and moxifloxacin administered daily with other anti-tuberculosis drugs is highly active in mouse models of tuberculosis chemotherapy. The objective of this phase 2 clinical trial was to determine the bactericidal activity, safety, and tolerability of a regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Conde, Marcus B., Mello, Fernanda C. Q., Duarte, Rafael Silva, Cavalcante, Solange C., Rolla, Valeria, Dalcolmo, Margareth, Loredo, Carla, Durovni, Betina, Armstrong, Derek T., Efron, Anne, Barnes, Grace L., Marzinke, Mark A., Savic, Radojka M., Dooley, Kelly E., Cohn, Silvia, Moulton, Lawrence H., Chaisson, Richard E., Dorman, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861335/
https://www.ncbi.nlm.nih.gov/pubmed/27159505
http://dx.doi.org/10.1371/journal.pone.0154778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861335/
https://www.ncbi.nlm.nih.gov/pubmed/27159505
http://dx.doi.org/10.1371/journal.pone.0154778

Ejemplares similares